These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24846083)

  • 1. A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making.
    Oberije C; Nalbantov G; Dekker A; Boersma L; Borger J; Reymen B; van Baardwijk A; Wanders R; De Ruysscher D; Steyerberg E; Dingemans AM; Lambin P
    Radiother Oncol; 2014 Jul; 112(1):37-43. PubMed ID: 24846083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients.
    Dehing-Oberije C; De Ruysscher D; Petit S; Van Meerbeeck J; Vandecasteele K; De Neve W; Dingemans AM; El Naqa I; Deasy J; Bradley J; Huang E; Lambin P
    Radiother Oncol; 2010 Dec; 97(3):455-61. PubMed ID: 21084125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.
    Dankers FJWM; Wijsman R; Troost EGC; Tissing-Tan CJA; Kwint MH; Belderbos J; de Ruysscher D; Hendriks LE; de Geus-Oei LF; Rodwell L; Dekker A; Monshouwer R; Hoffmann AL; Bussink J
    Radiother Oncol; 2018 Nov; 129(2):249-256. PubMed ID: 30241789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
    Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer: A clinical prediction model-based approach.
    Karsten RT; Stuiver MM; van der Molen L; Navran A; de Boer JP; Hilgers FJM; Klop WMC; Smeele LE
    Oral Oncol; 2019 Jan; 88():172-179. PubMed ID: 30616790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Mehmood Q; Sun A; Becker N; Higgins J; Marshall A; Le LW; Vines DC; McCloskey P; Ford V; Clarke K; Yap M; Bezjak A; Bissonnette JP
    J Thorac Oncol; 2016 Feb; 11(2):213-21. PubMed ID: 26718880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer.
    Szuecs M; Kuhnt T; Punke C; Witt G; Klautke G; Kramp B; Hildebrandt G
    J Radiat Res; 2015 Jan; 56(1):159-68. PubMed ID: 25348250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.
    Schuette W; Krzakowski MJ; Massuti B; Otterson GA; Lizambri R; Wei H; Berger DP; Chen Y
    J Thorac Oncol; 2012 Jan; 7(1):157-64. PubMed ID: 22011667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
    Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
    Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
    Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
    Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and internal validation of a multinomial NTCP model for the severity of acute dyspnea after radiotherapy for lung cancer.
    Defraene G; Schuit E; De Ruysscher D
    Radiother Oncol; 2019 Jul; 136():176-184. PubMed ID: 31015122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
    Dandekar VK; Young J; Kiel K; Bonomi P; Fidler MJ; Batus M; Sher DJ
    Am J Clin Oncol; 2015 Dec; 38(6):605-9. PubMed ID: 24781341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions.
    De Langhe S; De Meerleer G; De Ruyck K; Ost P; Fonteyne V; De Neve W; Thierens H
    Radiother Oncol; 2014 Jul; 112(1):95-9. PubMed ID: 24951017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
    Lobo JM; Dicker AP; Buerki C; Daviconi E; Karnes RJ; Jenkins RB; Patel N; Den RB; Showalter TN
    PLoS One; 2015; 10(3):e0116866. PubMed ID: 25837660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.
    Abe J; Lobo JM; Trifiletti DM; Showalter TN
    BMC Med Inform Decis Mak; 2017 Aug; 17(1):128. PubMed ID: 28836985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia.
    Jeene PM; Kuijper SC; van den Boorn HG; El Sharouni SY; Braam PM; Oppedijk V; Verhoeven RHA; Hulshof MCCM; van Laarhoven HWM
    Acta Oncol; 2022 Jul; 61(7):849-855. PubMed ID: 35651320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care.
    Lambrecht M; Mercier C; Geussens Y; Nuyts S
    Support Care Cancer; 2013 Oct; 21(10):2663-70. PubMed ID: 23686379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.
    Hunter KU; Lee OE; Lyden TH; Haxer MJ; Feng FY; Schipper M; Worden F; Prince ME; McLean SA; Wolf GT; Bradford CR; Chepeha DB; Eisbruch A
    Head Neck; 2014 Jan; 36(1):120-5. PubMed ID: 23729173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.